FOLH1 and neoplasm: PSMA expression would reduce in mCRPC lesions, reducing the sensitivity of68Ga-PSMA-PET/CT and18F-FDG-PET/CT can complement evaluation of the tumor heterogeneity in advanced prostate cancer.